# Kura Sushi USA, Inc.: financial statements, quarterly

KRUS · Nasdaq · CIK 1772177 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Aug 31

Pages: [Overview](/companies/krus.md) · [Financials](/companies/krus/financials.md) · [Filings](/companies/krus/filings.md) · [Insiders](/companies/krus/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/krus/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-08-31) | Q1 FY2024 (2023-11-30) | Q2 FY2024 (2024-02-29) | Q3 FY2024 (2024-05-31) | Q4 FY2024 (2024-08-31) | Q1 FY2025 (2024-11-30) | Q2 FY2025 (2025-02-28) | Q3 FY2025 (2025-05-31) | Q4 FY2025 (2025-08-31) | Q1 FY2026 (2025-11-30) | Q2 FY2026 (2026-02-28) | Q3 FY2026 (2026-05-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [54.9 d](/filings/0001193125-25-269773.md) | [51.5](/filings/0000950170-25-002849.md) | [57.3](/filings/0000950170-25-052106.md) | [63.1](/filings/0000950170-25-094616.md) | [66.0 d](/filings/0001193125-25-269773.md) | [64.5](/filings/0001193125-26-006355.md) | [64.9](/filings/0001193125-26-145622.md) | [74.0](/filings/0001193125-26-297529.md) | [79.4 d](/filings/0001193125-25-269773.md) | [73.5](/filings/0001193125-26-006355.md) | [80.0](/filings/0001193125-26-145622.md) | [85.9](/filings/0001193125-26-297529.md) |
| Operating income | $m | [2.2 d](/filings/0001193125-25-269773.md) | [(2.8)](/filings/0000950170-25-002849.md) | [(1.7)](/filings/0000950170-25-052106.md) | [(1.2)](/filings/0000950170-25-094616.md) | [(5.8) d](/filings/0001193125-25-269773.md) | [(1.5)](/filings/0001193125-26-006355.md) | [(4.6)](/filings/0001193125-26-145622.md) | [(0.2)](/filings/0001193125-26-297529.md) | [1.5 d](/filings/0001193125-25-269773.md) | [(3.7)](/filings/0001193125-26-006355.md) | [(2.2)](/filings/0001193125-26-145622.md) | [(0.0)](/filings/0001193125-26-297529.md) |
| Interest expense | $m | [0.0 d](/filings/0001193125-25-269773.md) | [0.0](/filings/0000950170-25-002849.md) | [0.0](/filings/0000950170-25-052106.md) | [0.0](/filings/0000950170-25-094616.md) | [0.0 d](/filings/0001193125-25-269773.md) | [0.0](/filings/0001193125-26-006355.md) | [0.0](/filings/0001193125-26-145622.md) | [0.0](/filings/0001193125-26-297529.md) | [0.0 d](/filings/0001193125-25-269773.md) | [0.0](/filings/0001193125-26-006355.md) | [0.0](/filings/0001193125-26-145622.md) | [0.0](/filings/0001193125-26-297529.md) |
| Income tax | $m | [0.2 d](/filings/0001193125-25-269773.md) | [0.0](/filings/0000950170-25-002849.md) | [0.1](/filings/0000950170-25-052106.md) | [0.1](/filings/0000950170-25-094616.md) | [0.0 d](/filings/0001193125-25-269773.md) | [0.0](/filings/0001193125-26-006355.md) | [0.0](/filings/0001193125-26-145622.md) | [0.1](/filings/0001193125-26-297529.md) | [0.0 d](/filings/0001193125-25-269773.md) | [0.0](/filings/0001193125-26-006355.md) | [0.1](/filings/0001193125-26-145622.md) | [0.0](/filings/0001193125-26-297529.md) |
| Net income | $m | [2.9 d](/filings/0001193125-25-269773.md) | [(2.0)](/filings/0000950170-25-094616.md) | [(1.0)](/filings/0000950170-25-094616.md) | [(0.6)](/filings/0000950170-25-094616.md) | [(5.2) d](/filings/0001193125-25-269773.md) | [(1.0)](/filings/0001193125-26-297529.md) | [(3.8)](/filings/0001193125-26-297529.md) | [0.6](/filings/0001193125-26-297529.md) | [2.3 d](/filings/0001193125-25-269773.md) | [(3.1)](/filings/0001193125-26-297529.md) | [(1.7)](/filings/0001193125-26-297529.md) | [0.4](/filings/0001193125-26-297529.md) |
| Diluted EPS | $ per share | not reported | [(0.18)](/filings/0000950170-25-002849.md) | [(0.09)](/filings/0000950170-25-052106.md) | [(0.05)](/filings/0000950170-25-094616.md) | not reported | [(0.08)](/filings/0001193125-26-006355.md) | [(0.31)](/filings/0001193125-26-145622.md) | [0.05](/filings/0001193125-26-297529.md) | not reported | [(0.25)](/filings/0001193125-26-006355.md) | [(0.14)](/filings/0001193125-26-145622.md) | [0.03](/filings/0001193125-26-297529.md) |
| Basic EPS | $ per share | not reported | [(0.18)](/filings/0000950170-25-002849.md) | [(0.09)](/filings/0000950170-25-052106.md) | [(0.05)](/filings/0000950170-25-094616.md) | not reported | [(0.08)](/filings/0001193125-26-006355.md) | [(0.31)](/filings/0001193125-26-145622.md) | [0.05](/filings/0001193125-26-297529.md) | not reported | [(0.25)](/filings/0001193125-26-006355.md) | [(0.14)](/filings/0001193125-26-145622.md) | [0.03](/filings/0001193125-26-297529.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-08-31) | Q1 FY2024 (2023-11-30) | Q2 FY2024 (2024-02-29) | Q3 FY2024 (2024-05-31) | FY2024 (2024-08-31) | Q1 FY2025 (2024-11-30) | Q2 FY2025 (2025-02-28) | Q3 FY2025 (2025-05-31) | FY2025 (2025-08-31) | Q1 FY2026 (2025-11-30) | Q2 FY2026 (2026-02-28) | Q3 FY2026 (2026-05-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [69.7](/filings/0000950170-24-124091.md) | [64.2](/filings/0000950170-24-001912.md) | [56.8](/filings/0000950170-24-041858.md) | [59.4](/filings/0000950170-24-082426.md) | [51.0](/filings/0001193125-25-269773.md) | [108](/filings/0000950170-25-002849.md) | [85.2](/filings/0000950170-25-052106.md) | [47.1](/filings/0000950170-25-094616.md) | [47.5](/filings/0001193125-26-297529.md) | [35.4](/filings/0001193125-26-006355.md) | [26.6](/filings/0001193125-26-145622.md) | [24.4](/filings/0001193125-26-297529.md) |
| Current assets | $m | [89.4](/filings/0000950170-24-124091.md) | [82.0](/filings/0000950170-24-001912.md) | [74.2](/filings/0000950170-24-041858.md) | [72.3](/filings/0000950170-24-082426.md) | [61.3](/filings/0001193125-25-269773.md) | [118](/filings/0000950170-25-002849.md) | [94.7](/filings/0000950170-25-052106.md) | [72.0](/filings/0000950170-25-094616.md) | [75.4](/filings/0001193125-26-297529.md) | [64.8](/filings/0001193125-26-006355.md) | [62.8](/filings/0001193125-26-145622.md) | [58.9](/filings/0001193125-26-297529.md) |
| Total assets | $m | [305](/filings/0000950170-24-124091.md) | [309](/filings/0000950170-24-001912.md) | [316](/filings/0000950170-24-041858.md) | [325](/filings/0000950170-24-082426.md) | [329](/filings/0001193125-25-269773.md) | [404](/filings/0000950170-25-002849.md) | [410](/filings/0000950170-25-052106.md) | [419](/filings/0000950170-25-094616.md) | [431](/filings/0001193125-26-297529.md) | [444](/filings/0001193125-26-006355.md) | [461](/filings/0001193125-26-145622.md) | [472](/filings/0001193125-26-297529.md) |
| Current liabilities | $m | [29.1](/filings/0000950170-24-124091.md) | [31.1](/filings/0000950170-24-001912.md) | [30.6](/filings/0000950170-24-041858.md) | [33.7](/filings/0000950170-24-082426.md) | [34.5](/filings/0001193125-25-269773.md) | [34.1](/filings/0000950170-25-002849.md) | [35.5](/filings/0000950170-25-052106.md) | [38.5](/filings/0000950170-25-094616.md) | [42.8](/filings/0001193125-26-297529.md) | [40.3](/filings/0001193125-26-006355.md) | [43.0](/filings/0001193125-26-145622.md) | [46.9](/filings/0001193125-26-297529.md) |
| Total liabilities | $m | [140](/filings/0000950170-24-124091.md) | [146](/filings/0000950170-24-001912.md) | [150](/filings/0000950170-24-041858.md) | [158](/filings/0000950170-24-082426.md) | [166](/filings/0001193125-25-269773.md) | [176](/filings/0000950170-25-002849.md) | [185](/filings/0000950170-25-052106.md) | [192](/filings/0000950170-25-094616.md) | [200](/filings/0001193125-26-297529.md) | [214](/filings/0001193125-26-006355.md) | [232](/filings/0001193125-26-145622.md) | [241](/filings/0001193125-26-297529.md) |
| Shareholders' equity | $m | [165](/filings/0001193125-25-269773.md) | [164](/filings/0000950170-25-094616.md) | [165](/filings/0000950170-25-094616.md) | [166](/filings/0000950170-25-094616.md) | [163](/filings/0001193125-26-297529.md) | [228](/filings/0001193125-26-297529.md) | [225](/filings/0001193125-26-297529.md) | [227](/filings/0001193125-26-297529.md) | [231](/filings/0001193125-26-297529.md) | [229](/filings/0001193125-26-297529.md) | [229](/filings/0001193125-26-297529.md) | [231](/filings/0001193125-26-297529.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-08-31) | Q1 FY2024 (2023-11-30) | Q2 FY2024 (2024-02-29) | Q3 FY2024 (2024-05-31) | Q4 FY2024 (2024-08-31) | Q1 FY2025 (2024-11-30) | Q2 FY2025 (2025-02-28) | Q3 FY2025 (2025-05-31) | Q4 FY2025 (2025-08-31) | Q1 FY2026 (2025-11-30) | Q2 FY2026 (2026-02-28) | Q3 FY2026 (2026-05-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [11.0 d](/filings/0001193125-25-269773.md) | [2.4](/filings/0000950170-25-002849.md) | [3.8 d](/filings/0000950170-25-052106.md) | [8.7 d](/filings/0000950170-25-094616.md) | [0.7 d](/filings/0001193125-25-269773.md) | [4.4](/filings/0001193125-26-006355.md) | [4.3 d](/filings/0001193125-26-145622.md) | [6.7 d](/filings/0001193125-26-297529.md) | [9.4 d](/filings/0001193125-25-269773.md) | [0.5](/filings/0001193125-26-006355.md) | [7.6 d](/filings/0001193125-26-145622.md) | [10.3 d](/filings/0001193125-26-297529.md) |
| Capital expenditure | $m | [11.9 d](/filings/0001193125-25-269773.md) | [9.4](/filings/0000950170-25-002849.md) | [13.5 d](/filings/0000950170-25-052106.md) | [11.1 d](/filings/0000950170-25-094616.md) | [10.3 d](/filings/0001193125-25-269773.md) | [11.6](/filings/0001193125-26-006355.md) | [11.6 d](/filings/0001193125-26-145622.md) | [13.6 d](/filings/0001193125-26-297529.md) | [9.5 d](/filings/0001193125-25-269773.md) | [13.8](/filings/0001193125-26-006355.md) | [15.4 d](/filings/0001193125-26-145622.md) | [14.0 d](/filings/0001193125-26-297529.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2022-11-30) | Q2 FY2023 (2023-02-28) | Q3 FY2023 (2023-05-31) | Q1 FY2024 (2023-11-30) | Q2 FY2024 (2024-02-29) | Q3 FY2024 (2024-05-31) | Q1 FY2025 (2024-11-30) | Q2 FY2025 (2025-02-28) | Q3 FY2025 (2025-05-31) | Q1 FY2026 (2025-11-30) | Q2 FY2026 (2026-02-28) | Q3 FY2026 (2026-05-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [9.8](/filings/0000950170-24-001912.md) | [9.8](/filings/0000950170-24-041858.md) | [10.8](/filings/0000950170-24-082426.md) | [11.2](/filings/0000950170-25-002849.md) | [11.2](/filings/0000950170-25-052106.md) | [11.2](/filings/0000950170-25-094616.md) | [11.4](/filings/0001193125-26-006355.md) | [12.1](/filings/0001193125-26-145622.md) | [12.3](/filings/0001193125-26-297529.md) | [12.1](/filings/0001193125-26-006355.md) | [12.1](/filings/0001193125-26-145622.md) | [12.4](/filings/0001193125-26-297529.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.